Cargando…

The Nuclear Hormone Receptor PPAR(γ) as a Therapeutic Target in Major Diseases

The peroxisome proliferator-activated receptor γ (PPAR(γ)) belongs to the nuclear hormone receptor superfamily and regulates gene expression upon heterodimerization with the retinoid X receptor by ligating to peroxisome proliferator response elements (PPREs) in the promoter region of target genes. O...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schmidt, Martina Victoria, Brüne, Bernhard, von Knethen, Andreas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	TheScientificWorldJOURNAL 2010
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5763724/ https://www.ncbi.nlm.nih.gov/pubmed/21057731 http://dx.doi.org/10.1100/tsw.2010.213

Ejemplares similares

Redox Regulation of PPARγ in Polarized Macrophages
por: Trümper, Verena, et al.
Publicado: (2020)

PPARγ1 attenuates cytosol to membrane translocation of PKCα to desensitize monocytes/macrophages
por: von Knethen, Andreas, et al.
Publicado: (2007)

PD-L1 in the palm of your hand: palmitoylation as a target for immuno-oncology
por: von Knethen, Andreas, et al.
Publicado: (2019)

5-Lipoxygenase contributes to PPARγ activation in macrophages in response to apoptotic cells
por: von Knethen, A, et al.
Publicado: (2012)

Nuclear receptor corepressors and PPARγ
por: Cohen, Ronald N.
Publicado: (2006)

Histone Deacetylation Inhibitors as Therapy Concept in Sepsis
por: von Knethen, Andreas, et al.
Publicado: (2019)

The Nuclear Receptor PPARγ as a Therapeutic Target for Cerebrovascular and Brain Dysfunction in Alzheimer's Disease
por: Nicolakakis, Nektaria, et al.
Publicado: (2010)

Activation of the peroxisome proliferator activated receptor γ counteracts sepsis-induced T-cell cytotoxicity towards alloantigenic target cells
por: Knethen, A von, et al.
Publicado: (2014)

Flow cytometry-based FRET identifies binding intensities in PPARγ1 protein-protein interactions in living cells
por: Trümper, Verena, et al.
Publicado: (2019)

Biochemical and structural basis for the pharmacological inhibition of nuclear hormone receptor PPARγ by inverse agonists
por: Irwin, Sean, et al.
Publicado: (2022)

Allosteric Pathways in the PPARγ-RXRα nuclear receptor complex
por: Ricci, Clarisse G., et al.
Publicado: (2016)

Cooperative cobinding of synthetic and natural ligands to the nuclear receptor PPARγ
por: Shang, Jinsai, et al.
Publicado: (2018)

Histone Deacetylation Inhibitors as Modulators of Regulatory T Cells
por: von Knethen, Andreas, et al.
Publicado: (2020)

Nuclear peroxisome proliferator activated receptor-gamma (PPARγ) as a therapeutic target to treat neurodegeneration and dependence elicited by drugs of abuse
por: Ciccocioppo, Roberto, et al.
Publicado: (2020)

PPARγ and PGC-1α as Therapeutic Targets in Parkinson’s
por: Corona, Juan Carlos, et al.
Publicado: (2014)

PPARγ as a Novel Therapeutic Target in Lung Cancer
por: Reddy, Aravind T., et al.
Publicado: (2016)

Macrophage S1PR1 Signaling Alters Angiogenesis and Lymphangiogenesis During Skin Inflammation
por: Syed, Shahzad Nawaz, et al.
Publicado: (2019)

Nuclear Receptor Cofactors in PPARγ-Mediated Adipogenesis and Adipocyte Energy Metabolism
por: Powell, Emily, et al.
Publicado: (2007)

Diverse coactivator recruitment through differential PPARγ nuclear receptor agonism
por: Lizcano, Fernando, et al.
Publicado: (2013)

Definition of functionally and structurally distinct repressive states in the nuclear receptor PPARγ
por: Heidari, Zahra, et al.
Publicado: (2019)

Nrf2, the Master Regulator of Anti-Oxidative Responses
por: Vomund, Sandra, et al.
Publicado: (2017)

Therapeutic Advantages of Dual Targeting of PPAR-δ and PPAR-γ in an Experimental Model of Sporadic Alzheimer’s Disease
por: Reich, D, et al.
Publicado: (2018)

Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis
por: Shirinsky, Ivan V., et al.
Publicado: (2011)

Potential Therapeutic Targets for PPARγ after Spinal Cord Injury
por: McTigue, Dana M.
Publicado: (2008)

Therapeutic Opportunities for Intestinal Angioectasia‐ Targeting PPARγ and Oxidative Stress
por: Sarangdhar, Mayur, et al.
Publicado: (2020)

Erratum: “The Role of Dietary Phytoestrogens and the Nuclear Receptor PPARγ in Adipogenesis: An in Vitro Study”
por: Hall, Julie M., et al.
Publicado: (2019)

Is peroxisome proliferator-activated receptor gamma (PPARγ) a therapeutic target for the treatment of pulmonary hypertension?
por: Green, David E., et al.
Publicado: (2011)

Therapeutic Implications of PPARγ in Human Osteosarcoma
por: Wagner, Eric R., et al.
Publicado: (2010)

Therapeutic Implications of PPARγ in Cardiovascular Diseases
por: Hasegawa, Hiroshi, et al.
Publicado: (2010)

PPAR-γ: Therapeutic Potential for Multiple Sclerosis
por: Drew, Paul D., et al.
Publicado: (2008)

Therapeutic Potential of PPARγ Activation in Stroke
por: Vemuganti, Raghu
Publicado: (2008)

Nuclear Peroxisome Proliferator-Activated Receptors (PPARs) as Therapeutic Targets of Resveratrol for Autism Spectrum Disorder
por: Barone, Rita, et al.
Publicado: (2019)

Nuclear Receptor PPARα as a Therapeutic Target in Diseases Associated with Lipid Metabolism Disorders
por: Hu, Ping, et al.
Publicado: (2023)

PPARγ as a therapeutic target to rescue mitochondrial function in neurological disease
por: Corona, Juan Carlos, et al.
Publicado: (2016)

Scaffold-Based Pan-Agonist Design for the PPARα, PPARβ and PPARγ Receptors
por: Zhang, Li-Song, et al.
Publicado: (2012)

Regulation of adipogenesis by nuclear receptor PPARγ is modulated by the histone demethylase JMJD2C
por: Lizcano, Fernando, et al.
Publicado: (2011)

PPARγ Agonists: Potential as Therapeutics for Neovascular Retinopathies
por: Pershadsingh, Harrihar A., et al.
Publicado: (2008)

Underexpression of peroxisome proliferator-activated receptor (PPAR)γ in PAX8/PPARγ-negative thyroid tumours
por: Marques, A R, et al.
Publicado: (2004)

Expression of peroxisome proliferator-activated receptor (PPAR)γ in gastric cancer and inhibitory effects of PPARγ agonists
por: Sato, H, et al.
Publicado: (2000)

Selective modulator of nuclear receptor PPARγ with reduced adipogenic potential ameliorates experimental nephrotic syndrome
por: Bryant, Claire, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_irfd4a9nu1gnd5e7i87jnb809m